🇺🇸 FDA
Pipeline program

VEGF inhibitor PTC299

AMC-059

Phase 2 small_molecule terminated

Quick answer

VEGF inhibitor PTC299 for Kaposi's Sarcoma is a Phase 2 program (small_molecule) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PTC THERAPEUTICS, INC.
Indication
Kaposi's Sarcoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials